Fulcrum Therapeutics Appoints New CMO, Elects Directors
Ticker: FULC · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1680581
| Field | Detail |
|---|---|
| Company | Fulcrum Therapeutics, INC. (FULC) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $7.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-of-directors, appointment
TL;DR
Fulcrum Therapeutics just hired a new Chief Medical Officer and added two directors to the board.
AI Summary
Fulcrum Therapeutics, Inc. announced on June 17, 2024, the appointment of Dr. S. Brooks Marshall as Chief Medical Officer and the election of Dr. Marshall and Ms. Jennifer L. D. Allison to its Board of Directors. The company also reported on compensatory arrangements for its named executive officers and matters submitted to a vote of security holders.
Why It Matters
Key leadership changes and board appointments can signal strategic shifts and impact the company's future direction and operational effectiveness.
Risk Assessment
Risk Level: medium — Leadership changes and board composition shifts can introduce uncertainty and affect strategic execution.
Key Players & Entities
- Fulcrum Therapeutics, Inc. (company) — Registrant
- Dr. S. Brooks Marshall (person) — Appointed Chief Medical Officer and elected to Board of Directors
- Ms. Jennifer L. D. Allison (person) — Elected to Board of Directors
- June 17, 2024 (date) — Date of Report
FAQ
Who has been appointed as the new Chief Medical Officer of Fulcrum Therapeutics?
Dr. S. Brooks Marshall has been appointed as the new Chief Medical Officer of Fulcrum Therapeutics.
Who were elected to the Board of Directors of Fulcrum Therapeutics?
Dr. S. Brooks Marshall and Ms. Jennifer L. D. Allison were elected to the Board of Directors of Fulcrum Therapeutics.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 17, 2024.
What is the principal executive office address for Fulcrum Therapeutics?
The principal executive office address is 26 Landsdowne Street, Cambridge, Massachusetts, 02139.
What are the main items reported in this Form 8-K filing?
This Form 8-K reports on the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, and submission of matters to a vote of security holders.
Filing Stats: 939 words · 4 min read · ~3 pages · Grade level 12.2 · Accepted 2024-06-17 16:37:31
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share FULC The Nasdaq Global Ma
- $7.00 — at an exercise price per share equal to $7.00 per share, the closing price on the Nas
Filing Documents
- d845947d8k.htm (8-K) — 33KB
- 0001193125-24-162653.txt ( ) — 154KB
- fulc-20240617.xsd (EX-101.SCH) — 3KB
- fulc-20240617_lab.xml (EX-101.LAB) — 18KB
- fulc-20240617_pre.xml (EX-101.PRE) — 11KB
- d845947d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. FULCRUM THERAPEUTICS, INC. Date: June 17, 2024 By: /s/ Curtis Oltmans Name: Curtis Oltmans Title: Chief Legal Officer